C07C 311/43
Having the nitrogen atom of at least one of the sulfonamide groups
Official title: having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a ring other than a six-membered aromatic ring
C07C311/43 (Having the nitrogen atom of at least one of the sulfonamide groups) appears on 29 US grants and 27 published applications in this corpus.
Search patents in C07C- Granted patents
- 29
- Published applications
- 27
- Assignees
- 27
- Inventors
- 119
- Latest grant
- 21 Apr 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1994 | 1 | 0 |
| 1995 | 4 | 0 |
| 1996 | 1 | 0 |
| 1997 | 0 | 0 |
| 1998 | 0 | 0 |
| 1999 | 0 | 0 |
| 2000 | 1 | 0 |
| 2001 | 1 | 0 |
| 2002 | 3 | 2 |
| 2003 | 1 | 1 |
| 2004 | 1 | 3 |
| 2005 | 1 | 1 |
| 2006 | 1 | 0 |
| 2007 | 2 | 2 |
| 2008 | 0 | 1 |
| 2009 | 1 | 0 |
| 2010 | 0 | 4 |
| 2011 | 0 | 1 |
| 2012 | 2 | 0 |
| 2013 | 0 | 0 |
| 2014 | 1 | 0 |
| 2015 | 2 | 0 |
| 2016 | 0 | 0 |
| 2017 | 0 | 0 |
| 2018 | 0 | 0 |
| 2019 | 0 | 2 |
| 2020 | 1 | 0 |
| 2021 | 1 | 1 |
| 2022 | 0 | 3 |
| 2023 | 0 | 2 |
| 2024 | 0 | 2 |
| 2025 | 2 | 2 |
| 2026 | 2 | 0 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Methods of treating cancer21 Apr 2026US 12,606,521 B2Institute For Cancer Research
- Methods and compositions for targeting Tregs using CCR8 inhibitors17 Feb 2026US 12,552,753 B2Nanjing Immunophage Biomedical Co., Ltd.
- Phenylalanine-based LAT1 inhibitors and uses thereof30 Sep 2025US 12,427,124 B1Maxymune Therapeutics, Inc.
- WDR5-MYC inhibitors26 Aug 2025US 12,398,097 B2Vanderbilt University
- 3,4-disubstituted 3-cyclobutene-1,2-diones and use thereof28 Dec 2021US 11,208,377 B2Allergan, Inc.
- Phenylalanine-based lat1 inhibitors and uses thereof6 Nov 2025US 2025/0339388 A1Maxymune Therapeutics, Inc.
- Phenylalanine-based lat1 inhibitors and uses thereof16 Oct 2025US 2025/0319046 A1Maxymune Therapeutics, Inc.
- 3,4-disubstituted 3-cyclobutene-1,2-diones and use thereof5 Dec 2024US 2024/0400501 A1Allergan, Inc.
- Methods of treating cancer13 Jun 2024US 2024/0190817 A1Institute For Cancer Research
- Methods and Compositions for Targeting Tregs using CCR8 Inhibitors25 May 2023US 2023/0159446 A1Nanjing Immunophage Biomedical Co., Ltd.
Most cited
By later US patents
- Substituted isoquinolinyl-1-2-diaminocyclobutene-3,4,-diones34US 5,397,790 AAmerican Home Products Corporation · 1995
- Biphenyl and biphenyl-analogous compounds as integrin antagonists31US 6,420,396 B1Beiersdorf AG · 2002
- Substituted n-heteroaryl-1, 2-diaminocyclobutene-3, 3-diones24US 5,401,753 AAmerican Home Products Corporation · 1995
- Substituted N-aryl-1,2-diaminocyclobutene-3,4-diones23US 5,403,853 AAmerican Home Products Corporation · 1995
- Substituted N-heteroaryl and N-aryl-1,2-diaminocyclobutene-3,4-diones22US 5,506,252 AAmerican Home Products Corporation · 1996